Evaluation of Losartan on Cardiovascular Disease in Patients With Mucopolysaccharidoses IV A and VI

Hospital de Clinicas de Porto Alegre

Status and phase

Active, not recruiting

Phase 2

Conditions

MPS IV A

Morquio Syndrome

MPS - Mucopolysaccharidosis

Mucopolysaccharidosis IV A

Morquio Syndrome A

MPS VI

Mucopolysaccharidoses

Mucopolysaccharidosis VI

Morquio A Syndrome

Treatments

Drug: Losartan

Drug: Placebo

Study type

Interventional

Funder types

Other

Identifiers

NCT03632213

17-0685

Details and patient eligibility

About

Mucopolysaccharidoses (MPS) are multisystemic diseases with significant clinical overlap between their types, with cardiac problems being among the most commonly observed manifestations and are also among the main causes of mortality in these patients. For some of the cardiovascular manifestations, such as aortic root dilation and valve diseases, there is no effective treatment currently available. Losartan, on the other hand, has been shown to be an effective drug for dilation of the aortic root, at least in animal models. This study aims to evaluate the safety and efficacy of losartan in patients with MPS VI and other mucopolysaccharidoses.

Full description

Mucopolysaccharidoses (MPS) are a group of lysosomal diseases characterized by deficiency of enzymes responsible for the degradation of glycosaminoglycans. MPS are multisystemic diseases with significant clinical overlap between their types, with cardiac problems being among the most commonly observed manifestations and are also among the main causes of mortality in these patients. Enzyme replacement therapy and bone marrow transplantation, despite being well established treatments, are not yet capable of reversing or preventing the progression of some of the cardiological manifestations of MPS. On the other hand, these patients may benefit from other conventional drug or surgical treatment, which can be instituted at an appropriate time if there is a better understanding of how these manifestations progress. In particular, the occurrence of aortic root dilation, although described in animal models, has only recently been evaluated in the studies on mucopolysaccharidoses.

In addition, verifying the effectiveness of losartan in controlling these manifestations in the animal model opens the perspective of clinical use of this drug. Losartan is a low-cost drug and, if its efficacy is demonstrated, may represent an accessible therapy directed at the unmet needs of these patients.

Enrollment

10 patients

Sex

All

Ages

10 to 40 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Confirmed biochemical or molecular diagnosis of MPS VI or MPS IVA.
Age between 10 and 40 years.
Presence of aortic root diameter greater than 1.0 standard deviation, as determined by local measurement.
Be in a stable treatment regime in the last 3 months (without performing Enzyme replacement therapy (ERT), or performing ERT on a regular basis).
Patient who agree to participate in the study protocol by signing a free informed consent form.

Exclusion criteria

Patient who underwent previous aortic surgery.
Patient with aortic root diameter greater than 5 cm.
Patient on angiotensin-converting-enzyme (ACE) inhibitor. In case of use of beta-blocker, or calcium channel blocker, patient without adequate control of blood pressure in the last 3 months.
Patients with previous adverse events related to treatment with losartan or contraindication to this treatment.
Inability, in the opinion of the investigator, to complete the study procedures.